BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 19493273)

  • 21. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
    Katayama K; Shibata K; Mitsuhashi J; Noguchi K; Sugimoto Y
    Anticancer Res; 2009 Apr; 29(4):1059-65. PubMed ID: 19414346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
    Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
    Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
    Imai Y; Asada S; Tsukahara S; Ishikawa E; Tsuruo T; Sugimoto Y
    Mol Pharmacol; 2003 Sep; 64(3):610-8. PubMed ID: 12920197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
    Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells.
    Svirnovski AI; Shman TV; Serhiyenka TF; Savitski VP; Smolnikova VV; Fedasenka UU
    Hematology; 2009 Aug; 14(4):204-12. PubMed ID: 19635183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
    Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Yang CH; Huang CJ; Yang CS; Chu YC; Cheng AL; Whang-Peng J; Yang PC
    Cancer Res; 2005 Aug; 65(15):6943-9. PubMed ID: 16061679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).
    Tournier N; Chevillard L; Megarbane B; Pirnay S; Scherrmann JM; Declèves X
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):905-15. PubMed ID: 19887017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
    Gupta A; Zhang Y; Unadkat JD; Mao Q
    J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
    Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Imai Y; Tsukahara S; Ishikawa E; Tsuruo T; Sugimoto Y
    Jpn J Cancer Res; 2002 Mar; 93(3):231-5. PubMed ID: 11927002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.